The Future of Intraoperative Pathology

Real-time, gold-standard margin assessment, without labels or slides

The Burning Issue

1M+ U.S. cancer surgeries per year

Up to 30% require re-operation due to

post-surgical findings

0 reliable tools for real-time,

reliable tumor characterization in the OR

A New Path to Precision

Gold-standard pathology in under 10 minutes

No slides. No stains. No labs.

Across the entire tissue surface

Right in the OR

Impact

For Patients

For Health Systems

For Surgeons

Fewer re-operations.

Less time under anesthesia.

Faster recovery.

For Surgeons

For Health Systems

For Surgeons

Immediate, actionable pathological insight.

Confident resection decisions in real time.

No more waiting on the lab.

For Health Systems

Fewer costly return-to-OR cases.

Shorter operative times.

Stronger outcomes metrics.

About NIO Path

Precision Pathology, From the Inside Out

NIO Path is an early-stage medical technology company focused on transforming intraoperative cancer care. Our mission is to enable real-time, high-fidelity tumor margin assessment directly in the OR, eliminating delays and reducing the need for repeat surgeries. Founded by experts in AI and photoacoustic imaging, we are building a new path for surgical precision.

NIO Path

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept